Muto Y - Search Results

1

Nutritional pharmacotherapy of chronic liver disease: from support of liver failure to prevention of liver cancer.

Moriwaki H, Tajika M, Miwa Y, Kato M, Yasuda I, Shiratori Y, Okuno M, Kato T, Ohnishi H, Muto Y. Moriwaki H, et al. Among authors: muto y. J Gastroenterol. 2000;35 Suppl 12:13-7. J Gastroenterol. 2000. PMID: 10779208

2

Effects of branched-chain amino acid infusion on protein metabolism in rats with acute hepatic failure.

Miwa Y, Kato M, Moriwaki H, Okuno M, Sugihara J, Ohnishi H, Yoshida T, Muto Y, Nakayama M, Morioka Y, et al. Miwa Y, et al. Among authors: muto y. Hepatology. 1995 Jul;22(1):291-6. Hepatology. 1995. PMID: 7601423

3

[Impaired metabolism of amino acid and protein in patients with liver cirrhosis].

Kato M, Moriwaki H, Muto Y. Kato M, et al. Among authors: muto y. Nihon Rinsho. 1994 Jan;52(1):145-9. Nihon Rinsho. 1994. PMID: 8114284 Japanese.

4

[Recent advances in the treatment of decompensated liver cirrhosis].

Moriwaki H, Kato M, Murase M, Muto Y. Moriwaki H, et al. Among authors: muto y. Nihon Rinsho. 1994 Jan;52(1):192-6. Nihon Rinsho. 1994. PMID: 8114292 Japanese.

5

[Liver failure (hepatic failure)].

Muto Y, Moriwaki H, Ohnishi H, Sugihara J. Muto Y, et al. Ryoikibetsu Shokogun Shirizu. 1995;(7):239-42. Ryoikibetsu Shokogun Shirizu. 1995. PMID: 8749461 Review. Japanese. No abstract available.

6

Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis.

Kato M, Miwa Y, Tajika M, Hiraoka T, Muto Y, Moriwaki H. Kato M, et al. Among authors: muto y. Intern Med. 1998 May;37(5):429-34. doi: 10.2169/internalmedicine.37.429. Intern Med. 1998. PMID: 9652895 Free article.

7

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma.

Muto Y, Moriwaki H, Shiratori Y. Muto Y, et al. Digestion. 1998 Jul;59 Suppl 2:89-91. doi: 10.1159/000051435. Digestion. 1998. PMID: 9718434 Review. No abstract available.

8

Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma.

Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y. Moriwaki H, et al. Among authors: muto y. Clin Cancer Res. 1997 May;3(5):727-31. Clin Cancer Res. 1997. PMID: 9815742 Clinical Trial.

9

[Acute-on-chronic liver failure].

Ohnishi H, Sugihara J, Moriwaki H, Muto Y. Ohnishi H, et al. Among authors: muto y. Ryoikibetsu Shokogun Shirizu. 1995;(7):217-9. Ryoikibetsu Shokogun Shirizu. 1995. PMID: 8749457 Review. Japanese. No abstract available.

10

Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5).

Fukutomi Y, Omori M, Muto Y, Ninomiya M, Okuno M, Moriwaki H. Fukutomi Y, et al. Among authors: muto y. Jpn J Cancer Res. 1990 Dec;81(12):1281-5. doi: 10.1111/j.1349-7006.1990.tb02691.x. Jpn J Cancer Res. 1990. PMID: 1703522 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,011 results

Search Page

Filters